# IDH1 Peptide Vaccine for Recurrent Grade II Glioma

> **NCT02193347** · PHASE1 · COMPLETED · sponsor: **Katy Peters, MD, PhD** · enrollment: 24 (actual)

## Conditions studied

- Brain Cancer
- Brain Neoplasm, Primary
- Brain Neoplasms, Recurrent
- Brain Tumor
- Cancer of the Brain

## Interventions

- **BIOLOGICAL:** PEPIDH1M vaccine
- **BIOLOGICAL:** Tetanus-Diphtheria Toxoid (Td)
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02193347
- **Lead sponsor:** Katy Peters, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-28
- **Primary completion:** 2020-02-03
- **Final completion:** 2020-02-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193347, "IDH1 Peptide Vaccine for Recurrent Grade II Glioma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02193347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*